To determine whether the enhanced immune response contributed to the anti-tumor effects, 4T1-tumor bearing mice were subjected to CD8+ T cell ablation using CD8-depleting antibodies during P-BS-CM1 → P-PS-CM2 (+) treatment. This evidence concerns the gene CD8A and neoplasm.